Adverum Biotechnologies to Present At Phacilitate Cell & Gene Therapy World 2017
Session: Vector Manufacturing: Meeting Escalating Demand for In Vivo and Ex Vivo Gene Therapy Applications
Topic: What are your options to alleviate the inefficiency of current AAV, retroviral and lentiviral vector manufacturing systems and minimize impact on cost of goods?
Session: Therapeutic Area R&D Update: CNS & Ophthalmology
Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha-1 antitrypsin (A1AT) deficiency, and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with
Contacts for Adverum:
Leone PattersonChief Financial Officer Adverum Biotechnologies, Inc.650-665-7222 firstname.lastname@example.org Jill SteierSenior Vice President The Trout Group LLC646-378-2946 email@example.com